BRD4 Inhibitor-33, with the CAS number 1445993-17-8, is a small molecule compound that selectively inhibits the bromodomain-containing protein 4 (BRD4), which is involved in the regulation of gene expression and has been implicated in various cancers and inflammatory diseases. This compound is characterized by its ability to disrupt the interaction between BRD4 and acetylated lysines on histones, thereby influencing transcriptional regulation. Typically, BRD4 inhibitors like BRD4 Inhibitor-33 exhibit high affinity and specificity for their target, making them valuable in research and potential therapeutic applications. The compound is often evaluated for its efficacy in preclinical studies, focusing on its impact on cell proliferation, apoptosis, and other cellular processes in cancer models. Additionally, BRD4 Inhibitor-33 may possess favorable pharmacokinetic properties, such as good solubility and metabolic stability, which are essential for its development as a therapeutic agent. Overall, BRD4 Inhibitor-33 represents a promising avenue for targeted cancer therapy and the modulation of epigenetic regulation.

BRD4 Inhibitor-33

1445993-17-8: BRD4 Inhibitor-33, with the CAS number 1445993-17-8, is a small molecule compound that selectively inhibits the bromodomain-containing protein 4 (BRD4), which is involved in the regulation of gene expression and has been implicated in various cancers and inflammatory diseases. This compound is characterized by its ability to disrupt the interaction between BRD4 and acetylated lysines on histones, thereby influencing transcriptional regulation. Typically, BRD4 inhibitors like BRD4 Inhibitor-33 exhibit high affinity and specificity for their target, making them valuable in research and potential therapeutic applications. The compound is often evaluated for its efficacy in preclinical studies, focusing on its impact on cell proliferation, apoptosis, and other cellular processes in cancer models. Additionally, BRD4 Inhibitor-33 may possess favorable pharmacokinetic properties, such as good solubility and metabolic stability, which are essential for its development as a therapeutic agent. Overall, BRD4 Inhibitor-33 represents a promising avenue for targeted cancer therapy and the modulation of epigenetic regulation.

<p>BRD4 Inhibitor-33 (example 13), a potent inhibitor of BRD4, is applicable in research related to both acute and chronic kidney diseases [1].</p>

CAS 1445993-17-8

BRD4 Inhibitor-33

BRD4 Inhibitor-33

Ref: TM-T85911